Baidu
map

中药出国门了!中国与希腊开展传统医药科研合作

2019-11-12 牟媞媞 央视新闻客户端

记者从北京市卫生健康委了解到,北京市与希腊科斯市将共同建设“传统医药科研中心”,通过此项目带动“一带一路”沿线国家的天然药用植物资源研究与开发利用。 今后,双方将针对共有的天然药用资源进行实验和探索,对希腊药用资源引进中国前必要的基础研究进行合作。并开展中药质量标准化研究工作,健全完善中药国际标准。北京市中药研究所所长刘清泉表示,将用全球的眼光去寻求新的药物,“这样不仅仅它的药物资源会增

记者从北京市卫生健康委了解到,北京市与希腊科斯市将共同建设“传统医药科研中心”,通过此项目带动“一带一路”沿线国家的天然药用植物资源研究与开发利用。
 
今后,双方将针对共有的天然药用资源进行实验和探索,对希腊药用资源引进中国前必要的基础研究进行合作。并开展中药质量标准化研究工作,健全完善中药国际标准。

北京市中药研究所所长刘清泉表示,将用全球的眼光去寻求新的药物,“这样不仅仅它的药物资源会增加,对我们药物耐药性的研究等都会起到很好的作用。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016459, encodeId=860b2016459c1, content=<a href='/topic/show?id=7070e5009be' target=_blank style='color:#2F92EE;'>#科研合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75009, encryptionId=7070e5009be, topicName=科研合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Aug 18 19:36:00 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375357, encodeId=8adf3e535775, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:04:27 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409933, encodeId=baf114099338f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542067, encodeId=3ad3154206edf, content=<a href='/topic/show?id=d15d484e110' target=_blank style='color:#2F92EE;'>#希腊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48471, encryptionId=d15d484e110, topicName=希腊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=740213344258, createdName=ms117281293605716, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2016459, encodeId=860b2016459c1, content=<a href='/topic/show?id=7070e5009be' target=_blank style='color:#2F92EE;'>#科研合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75009, encryptionId=7070e5009be, topicName=科研合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Aug 18 19:36:00 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375357, encodeId=8adf3e535775, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:04:27 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409933, encodeId=baf114099338f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542067, encodeId=3ad3154206edf, content=<a href='/topic/show?id=d15d484e110' target=_blank style='color:#2F92EE;'>#希腊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48471, encryptionId=d15d484e110, topicName=希腊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=740213344258, createdName=ms117281293605716, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-16 14794e5bm67(暂无昵称)

    非常受益,很好的研究

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2016459, encodeId=860b2016459c1, content=<a href='/topic/show?id=7070e5009be' target=_blank style='color:#2F92EE;'>#科研合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75009, encryptionId=7070e5009be, topicName=科研合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Aug 18 19:36:00 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375357, encodeId=8adf3e535775, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:04:27 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409933, encodeId=baf114099338f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542067, encodeId=3ad3154206edf, content=<a href='/topic/show?id=d15d484e110' target=_blank style='color:#2F92EE;'>#希腊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48471, encryptionId=d15d484e110, topicName=希腊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=740213344258, createdName=ms117281293605716, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-14 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=2016459, encodeId=860b2016459c1, content=<a href='/topic/show?id=7070e5009be' target=_blank style='color:#2F92EE;'>#科研合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75009, encryptionId=7070e5009be, topicName=科研合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Tue Aug 18 19:36:00 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375357, encodeId=8adf3e535775, content=非常受益,很好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Sat Nov 16 19:04:27 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409933, encodeId=baf114099338f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542067, encodeId=3ad3154206edf, content=<a href='/topic/show?id=d15d484e110' target=_blank style='color:#2F92EE;'>#希腊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48471, encryptionId=d15d484e110, topicName=希腊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=740213344258, createdName=ms117281293605716, createdTime=Thu Nov 14 14:36:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]

相关资讯

J Am Heart Assoc:万名急性心衰患者研究称:75%用中药,丹参或增死亡和出血风险

《美国心脏协会杂志》发表的一项针对China PEACE回顾性心衰研究的分析结果表明,在我国急性心衰住院患者中,74.7%应用中药,其中83.3%是静脉注射液。

这些中药大品种,被重点监控

截至目前,全国范围的三级公立医院落实绩效考核方案,限制辅助用药使用,与此同时,已有多地出台地方版重点监控目录,其在国家版的基础上扩充品种数量,覆盖了不少中药品种。

理想的中药出口日本欧洲,绝大部分中国人吃不到

出口的一批枸杞,在欧洲因为农药残留不合格而被扣留。对于李贵这种小型的药材出口公司而言,“自动扣留”无疑杀伤力巨大。

中药注射剂进入生死局 安全性再评价或成出路

中药注射剂是我国中医药特色产物,是中药现代化发展过程中的产物之一。中药注射剂参照注射剂的标准,从中药材(单味或复方)中提取某些活性组分、有效部位或有效成分作为原料研制而成。其安全性一直饱受争议,退市呼声不绝于耳,通过安全性再评价实现产品的优胜劣汰,或成为中药注射剂产业走出困境的唯一出路。

全新中西药配伍禁忌表

中西药联用是目前普遍采取的用药方式,且疗效显着。但我们在联合用药的过程中,如果不注意药物之间的不良反应,轻则减效或无效,重则导致中毒甚至死亡,所以临床上必须引起重视。

官方文件流出:这些西医,可以开中药了

这些西医,可以开中药了。

Baidu
map
Baidu
map
Baidu
map